This report was first published by Endpoints News. To see the original version, click here
Ocular Therapeutix’ investigational drug could become the preferred therapy for wet age-related macular degeneration after data released Tuesday showed statistical superiority to Regeneron and Bayer’s current bestseller Eylea.
However, the data from the trial appear to have disappointed, and the company’s stock $OCUL was down about 22% at market open.
您已阅读8%（442字），剩余92%（4966字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。